Pharmacologic Cardioversion of Atrial Fibrillation: Always the Same Algorithm or Different Drugs for Different Patients?

  • N. Baldi
  • V. A. Russo
  • G. Marasco
  • G. Polimeni
  • V. Morrone
Conference paper


The clinical use of class IC antiarrhythmic drugs and amiodarone during the last 10 years has represented a great achievement in the restoration of the sinus rhythm during atrial fibrillation (AF) of recent onset. In fact, the advantages of the pharmacologic treatment depend not only on the effectiveness of these drugs (quinidine, a very old drug, has also shown an effectiveness in the range of 30% – 91%), but much more on the velocity of the sinus rhythm restoration, often during the intravenous infusion of the drug. This avoids patient hospitalization. The drugs mainly employed in the treatment of AF are 1A and 1C antiarrhythmic agents, amiodarone, and sometimes verapamil, beta-blocking agents, and digoxin. Clinical practice suggests that the appropriate drug be chosen in each individual situation. However, before discussing the different clinical situations in which AF may occur, we must emphasize that to our knowledge no homogeneous, controlled, and randomized studies in large groups of patients that suggest the correct way of treating this arrhythmia have been performed. In fact, in all the studies patients the group were heterogenous as far as the etiology of heart disease and the duration of AF were different. In our opinion, however, it is possible to suggest some guidelines about the clinical use of different drugs in different patients using our knowledge of the electrophysiologic and hemodynamic properties of drugs, their effectiveness, and side effects occurring in clinical practice. Regarding cardioversion, if we take into account anticoagulant prophylaxis, it is useful to divide AF in-to AF of recent onset (less than 3 days) and prolonged AF (more than 3 days). In fact, according to the College of Chest Physicians (1), AF with a duration longer than 3 days needs to be treated with anticoagulant drugs for at least 3 weeks before cardioversion. Therefore, this practice identifies two groups of patients with AF: the first group can be treated within 3 days, and the second cannot be treated before 3 weeks. It is well known that AF duration is the main factor conditioning the probability of sinus rhythm restoration (2). As we now have several drugs whose effectiveness may be different according to AF duration, it follows that AF duration is one of the main factors determining the choice of drug.


Atrial Fibrillation Sinus Rhythm Accessory Pathway Lone Atrial Fibrillation Atrial Fibrillation Duration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dunn M, Alexander J, de Silva R, Hildner F (1989) Antithrombotic therapy in atrial fibrillation. Chest 95: 118S–124SPubMedCrossRefGoogle Scholar
  2. 2.
    Baldi N, Lenti V, Marasco G, Russo VA, Montervino C (1991) Riconversione della fibrillazione atriale: quando e perché. In Piccolo E, Raviele A (eds) Aritmie cardiache, Centro Scientifico Editore, Torino, pp 293–300Google Scholar
  3. 3.
    Goy ii, Gbric M, Hurni M, Finci L, Maendly R, Duc J, Sigwart U (1985) Conversion of supraventricular arrhythmias to sinus rhythm using flecainide. Eur Heart J 6: 518–524Google Scholar
  4. 4.
    Borgeat A, Goy JJ, Maendly R, Kaufman U, Grbic M, Sigwart U (1986) Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 58: 496–498PubMedCrossRefGoogle Scholar
  5. 5.
    Suttorp MJ, Kingma JH, Jessuron ER, Lie-A-Huen L, Van Hemel NM, Lie Kl (1990) The value of class 1C antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 16: 1722–1727PubMedCrossRefGoogle Scholar
  6. 6.
    Donovan KD, Dobb GJ, Coombs LJ, Kok-Yeng Lee, Week es JN, Murdock CJ, Clarke GM (1992) Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol 70: 50A–55APubMedCrossRefGoogle Scholar
  7. 7.
    Baldi N, Lenti V, Marasco G, Russo VA, Montervino C (1992) Propafenone vs flecainide in the acute treatment of atrial fibrillation of recent onset: a randomized study. New Trends Arrhith 8: 499–505Google Scholar
  8. 8.
    Capucci A, Gubelli S, Carini G, Frabetti L, Magnani B (1987) Cardioversione farmacologica con propafenone di fibrillazione atriale di recente insorgenza. G Ital Cardiol 17: 975–982PubMedGoogle Scholar
  9. 9.
    Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M (1989) Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 64: 335–338PubMedCrossRefGoogle Scholar
  10. 10.
    Bertini G, Conti A, Fradella G, Francardelli L, Giglioli G, Mangialavori G, Margheri M, Moschi G (1990) Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med 8: 15–20PubMedCrossRefGoogle Scholar
  11. 11.
    Bracchetti D, Palmieri M (1992) Sicurezza ed efficacia del propafenone e.v. nella cardioversione della fibrillazione atri-ale parossistica di recente insorgenza. G Ital Cardiol 23: 186 (abstr)Google Scholar
  12. 12.
    Faniel R, Schönfeld PG (1983) Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J 4: 180–185PubMedGoogle Scholar
  13. 13.
    Noc M, Stajer D, Horvat M (1990) Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 65: 679–680PubMedCrossRefGoogle Scholar
  14. 14.
    Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, Trisolino G, Della Casa S, Binetti N, Cavazza M, Sanguinetti M, Magnani B (1994) Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 74; 503–505PubMedCrossRefGoogle Scholar
  15. 15.
    Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ (1979) Ventricular fibrillation in the WolffParkinson-White syndrome. N Engl J Med 301: 1080–1085PubMedCrossRefGoogle Scholar
  16. 16.
    Wellens HJ, Durrer D (1973) Effect of digitalis on atrioventricular conduction and circus-movement tachycardias in patients with Wollf-Parkinson-White syndrome. Circulation 47: 1229–1233PubMedGoogle Scholar
  17. 17.
    Harper RW, Whitford E, Middlebrook K, Federman J, Anderson S, Pitt A (1982) Effect of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome. Am J Cardiol 50: 1323–1330PubMedCrossRefGoogle Scholar
  18. 18.
    Michel B, Goy JJ, Kappenberger L (1989) Syndrome de WolffParkinson-White et verapamil: à propos d’un cas de fibrillation auricolaire. Schweiz Med Wochenschr 13/119 (19): 630–634Google Scholar
  19. 19.
    Vitale P, De Stefano R, Auricchio A (1986) Possibile pericolosità dell’amiodarone per via endovenosa rapida nel corso di tachicardia da rientro in soggetti con Wolff-ParkinsonWhite. G ha] Cardiol 16: 969–974Google Scholar
  20. 20.
    Neuss H, Buss J, Schlepper M, Berthold R, Mitrovic V, Kramer A, Musial WJ (1983) Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-ParkinsonWhite syndrome. Eur Heart J 4: 347–353PubMedGoogle Scholar
  21. 21.
    Hellestrand KJ, Nathan AW, Bexton RS, Camm AJ (1984) Electrophysiologic effects of flectainide acetate on sinus node function anomalous atrioventricular connections and pacemaker threshold. Am J Cardiol 53 [Suppl B]: 30–38CrossRefGoogle Scholar
  22. 22.
    Breithardt G, Borggrefe M, Wiebringhaus E, Seipel L (1984) Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiological findings and long-term follow-up. Am J Cardiol 54: 29D–39DPubMedCrossRefGoogle Scholar
  23. 23.
    Kim SS, Lal R, Ruffy R (1986) Treatment of paroxysmal supraventricular tachycardia with flecainide acetate. Am J Cardiol 58: 80–85PubMedCrossRefGoogle Scholar
  24. 24.
    Shen EN, Keung E, Huycke E, Dohrmann ML, Nguyenn N, Morady F, Sung RJ (1986) Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study. Ann Intern Med 105: 655–659PubMedGoogle Scholar
  25. 25.
    Hammil SC, McLaran CJ, Wood DL, Osborne MJ, Gersh BJ, Holmes DR (1987) Double blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. J Am Coll Cardiol 9: 1364–1368CrossRefGoogle Scholar
  26. 26.
    Ludmer PL, McCowan NE, Antman EM, Friedman PL (1987) Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol 9: 1357–1363PubMedCrossRefGoogle Scholar
  27. 27.
    Dubuc M, Kus T, Campa MA, Lambert C, Rosengarten M, Shenasa M (1989) Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. Am Heart J 117:370–376PubMedCrossRefGoogle Scholar
  28. 28.
    Kappenberger LJ, Fromer MA, Shenasa M, Gloor HO (1985) Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. Clin Cardiol 8: 321–326PubMedCrossRefGoogle Scholar
  29. 29.
    Manolis AS, Salen DN, Estes NAm (1989) Electrophysiologic effects, efficacy and tolerance of class 1C antiarrhythmic agents in Wolff-Parkinson-White syndrome. Am J Cardiol 63: 746–750PubMedCrossRefGoogle Scholar
  30. 30.
    Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O (1990) Termination of acute atrial fibrillation in the WolffParkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol 16: 1408–1414PubMedCrossRefGoogle Scholar
  31. 31.
    Wellens HJ, Bar FW, Dassen WRM, Brugada P, Vanagt EG, Farre J (1980) Effect of drugs in the Wolff-Parkinson-White syndrome. Am J Cardiol 46: 665–669PubMedCrossRefGoogle Scholar
  32. 32.
    Asplund K, Beerman B, Bergfeld L, Blomstrom P, Blomstrom Lundqvist C, Boman K, Britton M, Dale J, Edvarsson N, For-fang K, Godtfredsen J, Gustafsson C, Juul-Moller S, Norrving B, Olsson SB, Rehnqvist N, Ronvall J (1993) Treatment of atrial fibrillation. Eur Heart J 14: 1427–1433CrossRefGoogle Scholar
  33. 33.
    Kerr CR, Prystowsky EN, Smith WM, Cook L, Gallagher JJ (1982) Electrophysiologic effects of disopyramide-phosphate in patients with Wolff-Parkinson-White syndrome. Circulation 65: 869–878PubMedCrossRefGoogle Scholar
  34. 34.
    Mitchell LB, Wyse DC, Duff HJ (1987) Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 76: 810–818PubMedCrossRefGoogle Scholar
  35. 35.
    Kunze KP, Schluter M, Kulk KH (1987) Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 75: 1050–1057PubMedCrossRefGoogle Scholar
  36. 36.
    Vik-Mo H, Ohm O-J, Lund-Johansen I (1982) Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction. Am J Cardiol 50: 1090–1094PubMedCrossRefGoogle Scholar
  37. 37.
    Reifel JA, Estes NAM, Waldo AL, Pristowsky EN, Di Bianco R (1994) A consensus report on antiarrhythmic drugs use. Clin Cardiol 17: 103–116CrossRefGoogle Scholar
  38. 38.
    Alboni P, Filippi L, Pirani R, Preziosi S, Paparella N (1984) Effetti elettrofisiologici del propafenone in pazienti con disfunzione del nodo del seno. G Ital Cardiol 14: 297–303PubMedGoogle Scholar
  39. 39.
    Ogunkelu JB, Damato AN, Akhtar M, Reddy CP, Caracta AR, Lau SH (1976) Electrophysiologic effects of procainamide in subtherapeutic to therapeutic doses on human atrioventricular conduction system. Am J Cardiol 37: 724–731PubMedCrossRefGoogle Scholar
  40. 40.
    Hellenstrand KJ, Bexton RS, Nathan AW, Spurrel RA, Camm AJ (1982) Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 48: 140–148CrossRefGoogle Scholar
  41. 41.
    Pristowsky EN, Heger JJ, Chilson DA, Miles WM, Hubbard J, Zipes DP (1984) Antiarrhythmic and electrophysiologic effects of oral propafenone. Am J Cardini 54: 26D–28DCrossRefGoogle Scholar
  42. 42.
    Finerman WB Jr, Peter TB, Mandel WJ (1980) Studies on the electrophysiologic effects of amiodarone in man. Circulation 62 [Suppl III]: 152Google Scholar
  43. 43.
    Schwartz A, Shen E, Morady F, Gillespie K, Scheinman M, Chatterjee K (1983) Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia. Am Heart J 106: 848–852PubMedCrossRefGoogle Scholar
  44. 44.
    Leach AJ, Brown JE, Armstrong PW (1980) Cardiac depression by intravenous disopyramide in patients with left ventricular dysfunction. Am J Med 68: 839–844PubMedCrossRefGoogle Scholar
  45. 45.
    Burton JR, Mathew MT, Armstrong PW (1976) Comparative effects of lidocaine and procainamide on acutely impaired hemodynamics. Am J Med 61: 215–220PubMedCrossRefGoogle Scholar
  46. 46.
    Legrand V, Vandormael M, Collgnon P, Kulbertus HE (1983) Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818) in coronary heart disease. Am J Cardiol 51: 422–426PubMedCrossRefGoogle Scholar
  47. 47.
    Podrid PJ, Cytryn R, Lown B (1984) Propafenone: non-invasive evaluation of efficacy. Am J Cardiol 54: 53D–59DPubMedCrossRefGoogle Scholar
  48. 48.
    Pentecost BI (1983) Myocardial infarction. In: Weatherall DJ, Ledingham JGG, Warrel DA (eds) Oxford Textbook of Medicine. Oxford University Press, Oxford, pp 174–188Google Scholar
  49. 49.
    Cowan JC, Gardiner P, Reid DS, Newell DJ, Campbell RWF (1986) A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction. J Cardiovasc Pharmacol 8: 252–256PubMedCrossRefGoogle Scholar
  50. 50.
    Levi F, Proto C (1972) Combined treatment of atrial fibrillation with quinidine and beta-blockers. Br Heart J 34: 911–914PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • N. Baldi
    • 1
  • V. A. Russo
    • 1
  • G. Marasco
    • 1
  • G. Polimeni
    • 1
  • V. Morrone
    • 1
  1. 1.Divisione di CardiologiaOspedale SS. AnnunziataTarantoItaly

Personalised recommendations